Demethylation medicines, IDH inhibitors, FLT3 inhibitors, and BCL-2 inhibitors are just a few medications that have recently been developed as a result of an improved understanding of the pathogenic pathways causing AML, including genetic characteristics and epigenetic changes. This evidence concerns the gene IDH1 and acute myeloid leukemia.